Aldeyra Therapeutics
ALDX
108 hedge funds and large institutions have $77.8M invested in Aldeyra Therapeutics in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 44 reducing their positions, and 37 closing their positions.
777% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $167K
23% more capital invested
Capital invested by funds: $63.3M → $77.8M (+$14.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.48% less ownership
Funds ownership: 62.04% → 60.56% (-1.5%)
16% less funds holding
Funds holding: 128 → 108 (-20)
30% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 44
49% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.37M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.79M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.58M |
| 4 |
D.E. Shaw & Co
New York
|
+$922K |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$860K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.31M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.53M |
| 3 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$1.23M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.13M |
| 5 |
Millennium Management
New York
|
-$1.09M |
ALDX Hedge Fund Activity: Q2 2026 in Review
108 institutional investors reported a position in Aldeyra Therapeutics (ALDX) for Q2 2026, worth a combined $77.8M — up 23% from $63.3M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ALDX and 19 opened new positions — a net loss of 18 holders — while 44 trimmed existing stakes and 31 added.
The largest buyer was Marshall Wace, adding an estimated $2.37M. The largest seller was BlackRock, cutting an estimated $4.31M.
- 108 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2026, down from 128 in Q1 2026.
- Funds reported $77.8M of Aldeyra Therapeutics stock for Q2 2026, up 23% quarter-over-quarter.
- 19 funds opened new Aldeyra Therapeutics positions in Q2 2026 and 37 closed out, a net change of -18 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2026 was Marshall Wace, an estimated $2.37M added.
- The largest Aldeyra Therapeutics seller in Q2 2026 was BlackRock, an estimated $4.31M sold.
Based on aggregated 13F filings for Q2 2026.